Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)
ID: 359001Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359001

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-25-013.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)" aimed at supporting preclinical research using adult stem cells. This initiative invites current recipients of prior RMIP grants to submit renewal applications that focus on late-stage preclinical studies, enhancing the development of safe and effective regenerative medicine therapies while addressing critical regulatory issues and promoting data sharing. The NIH plans to allocate up to $3.5 million in federal funds, with a requirement for successful applicants to match these funds with non-federal contributions on a 1:1 basis, as mandated by the 21st Century Cures Act. Interested applicants must adhere to specific guidelines and demonstrate significant collaboration with NIH staff, with applications due by October 21, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-25-013.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AR-25-013-Full-Announcement.html
    RFA-AR-25-013.html
    The National Institutes of Health (NIH) is releasing a funding opportunity aimed at supporting the Regenerative Medicine Innovation Project (RMIP) for preclinical research using adult stem cells. This opportunity, designated RFA-AR-25-013, invites current recipients of prior RMIP grants to submit renewal applications focusing on late-stage preclinical studies that enhance the development of safe and effective regenerative medicine therapies, addressing critical regulatory issues and promoting data sharing. The NIH aims to allocate up to $3.5 million from federal funds, requiring successful applicants to match these funds with non-federal contributions on a 1:1 basis, as stipulated by the 21st Century Cures Act. Applications are required to adhere to rigorous project plans demonstrating significance, innovation, and feasibility, and they must involve human-derived materials, ensuring no use of embryonic or fetal stem cells. Key project outcomes are expected to support the regulatory process for Investigational New Drug (IND) or Investigational Device Exemption (IDE) submissions. The application process emphasizes compliance with specific guidelines and necessitates significant collaboration with NIH staff. Overall, this funding initiative seeks to advance knowledge in regenerative medicine and its clinical applications while fostering robust partnerships within the research community.
    Similar Opportunities
    Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator- Initiated Studies (UH3 Clincical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies," aimed at advancing research in regenerative medicine utilizing adult stem cells. This initiative, supported by the 21st Century Cures Act, encourages small businesses to develop collaborative projects, although applications are not currently being solicited. The funding will be provided through a cooperative agreement, with an estimated synopsis posting date of August 1, 2025, and a closing date for applications expected by October 21, 2025. For further inquiries, interested parties can contact Aron Marquitz, Ph.D., at aron.marquitz@nih.gov or by phone at 301-435-1240.
    Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed)" aimed at advancing research in the engineering of stem cell-derived islet cells specifically for Type 1 Diabetes therapies. This grant seeks to support studies that enhance the intrinsic characteristics of these islet cell products, which are derived from well-defined cell bank sources, to improve graft viability and function through optimized banking, manufacturing, and quality control processes. With an estimated total program funding of $3 million and an award ceiling of $500,000, the NIH anticipates awarding approximately six grants, with applications due by March 7, 2026. For further inquiries, interested applicants can contact Albert Hwa at NIDDKDEM@nih.gov.
    Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies," aimed at advancing research in stem cell-derived islet cell products for enhanced cell replacement therapy outcomes. This initiative seeks to stimulate studies focused on engineering the inherent characteristics of these products, which are derived from well-defined cell bank sources, to improve graft viability and function, particularly in the context of type 1 diabetes. The estimated total program funding is $3 million, with approximately six awards expected, and interested applicants are encouraged to prepare collaborative proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release on August 1, 2025. For further inquiries, potential applicants can contact Dr. Albert J. Hwa at albert.hwa@nih.gov or by phone at 301-451-1525.
    Accelerating Product Excellence in Innovation and for Clinical Adoption (APEx) (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Accelerating Product Excellence in Innovation and for Clinical Adoption (APEx)" through a cooperative agreement aimed at supporting the development of extramural Resource Centers (RCs) focused on tissue engineering and regenerative medicine (TE/RM). The initiative seeks to foster interdisciplinary translational projects (ITPs) that leverage clinical, scientific, and regulatory expertise to advance therapeutics, diagnostics, and monitoring solutions for tissue damage caused by various health conditions. This funding cycle is particularly significant as it aims to facilitate the validation and preclinical testing of promising TE/RM products, with the goal of achieving regulatory approvals for first-in-human studies. Interested applicants, particularly small businesses with relevant expertise, are encouraged to prepare for future applications, as the estimated synopsis post date is October 7, 2025, with a closing date of November 7, 2025, and an anticipated award date of July 1, 2026. For further inquiries, potential applicants can contact Dr. Scott Verbridge at scott.verbridge@nih.gov or by phone at 301-594-0676.
    Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening," aimed at developing and validating advanced 3-D tissue models for drug efficacy testing. This initiative seeks to create non-animal models that accurately mimic the physiological properties of human tissues, thereby enhancing the predictive accuracy of drug screening processes. With an estimated total program funding of $1,600,000 and the expectation of awarding two grants, interested applicants are encouraged to utilize the resources available at the NCATS 3-D Bioprinting laboratory. The application process is open to various eligible entities, excluding non-domestic applicants, with a submission deadline anticipated by June 16, 2026. For further inquiries, potential applicants can contact Dobrila D. Rudnicki, Ph.D., at dobrila.rudnicki@nih.gov or by phone at 240-535-6621.
    Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing an upcoming funding opportunity titled "Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)," aimed at supporting research that leverages resources from ongoing clinical studies. This initiative encourages applications for ancillary studies that utilize well-characterized patient cohorts, infrastructure, data, and biological samples, while aligning with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). With an estimated total program funding of $600,000 and the expectation of awarding two grants, potential applicants are advised to begin developing collaborations and project proposals in advance of the official solicitation, which is expected to be published in early 2026. For further inquiries, interested parties may contact Dr. Heiyoung Park at Heiyoung.Park@nih.gov or by phone at 301-594-5032.
    Limited Competition: Competing Revisions to Support Clinical Trials in Somatic Cell Genome Editing (U19 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for competitive revisions to support clinical trials in somatic cell genome editing, specifically under the funding opportunity RFA-RM-24-008. This initiative aims to expand the existing Somatic Cell Genome Editing program by soliciting applications from awardees with active U19 awards funded under RFA-RM-22-015, which previously did not allow clinical trials. The funding will facilitate first-in-human genome editing clinical trials, including essential preparatory activities such as patient recruitment, regulatory approvals, and the development of clinical trial designs. Interested applicants must submit their proposals by February 13, 2026, and can find additional information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition Renewal for the Continuation of the Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Limited Competition Renewal for the Continuation of the Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required) under Funding Opportunity Number RFA-DK-26-308. This initiative aims to complete enrollment in the Liver Cirrhosis Network Cohort and the RESCU clinical studies, specifically targeting current grant recipients of RFA-DK-20-003, with a limit of one application per institution. The program is crucial for advancing clinical and translational research on cirrhosis treatments and outcomes, with the NIH planning to commit approximately $3.3 million in FY 2026 for up to ten awards, each with a maximum project period of five years. Applications are due by March 6, 2026, and interested parties can contact the Division of Digestive Diseases and Nutrition at NIDDKDDN@nih.gov for further information.
    Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Limited Competition Funding Opportunity titled "High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards." This initiative aims to support the development of unique capabilities and resources to address critical gaps in clinical and translational science within awarded UM1 Clinical and Translational Science Awards (CTSA) Program Hubs. The funding opportunity, numbered PAR-25-156, allows for project budgets of up to $500,000 per year over a project period of up to five years, with applications involving clinical trials being optional. Interested applicants, primarily from public and state-controlled institutions of higher education, must submit detailed integration plans, milestones, and sustainability evaluations by the closing date of September 28, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for competing revisions to existing Single Project Research Grants and Cooperative Agreements, with the option for clinical trials. This initiative allows NIH award recipients to apply for additional funds to expand their current projects within the relevant Institutes and Centers, specifically in response to Notices of Special Interest (NOSI) issued by participating NIH entities. The funding opportunity, identified as PA-23-317, is open to a wide range of eligible applicants, including higher education institutions, nonprofit organizations, and foreign entities, reflecting NIH's commitment to advancing impactful health research. Applications must be submitted by November 24, 2026, through the NIH ASSIST system or Grants.gov, and will be evaluated based on scientific merit and adherence to specified criteria. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov.